OBJECTIVE: Anxiety disorders (AD) and substance use disorders (SUD) commonly co-occur with bipolar disorder. This study was undertaken to assess AD-SUD-bipolar subtype interactions. METHODS: Extensive clinical interview and MINI were used to ascertain DSM-IV diagnoses of rapid cycling bipolar I (RCBPDI) or II (RCBPDII) disorder, SUDs, and ADs including generalized anxiety disorder (GAD), panic disorder (PD), and obsessive-compulsive disorder (OCD). Data at the initial assessment of four studies was used to compare the prevalence differences in ADs between RCBPDI and RCBPDII by using protocol-defined SUD categories, "Never," "Lifetime, but not recent," or "Recent." RESULTS: Five-hundred sixty-six of 568 patients (RCBPDI n=320, RCBPDII n=246) were eligible for analyses. In the "Never" group (n=191), patients with RCBPDI and RCBPDII had similar risk for ADs. In the "Lifetime, but not recent" group (n=195), RCBPDI patients had significantly higher risks for GAD (OR=3.29), PD (OR=2.95), but not OCD, compared with their RCBPDII counterparts. Similarly, in the "Recent" group (n=180), RCBPDI patients also had significantly higher risks for GAD (OR=3.6), PD (OR=3.8), but not OCD, compared with their RCBPDII counterparts. LIMITATIONS: Data were cross-sectional and not all ADs were included. CONCLUSION: In this large cohort of patients with rapid cycling bipolar disorder, risk for having GAD, PD, but not OCD increased significantly in patients with bipolar I disorder compared to their bipolar II counterparts when a history of SUD was present. However, there were no significant differences in the risk for GAD, PD, or OCD between the subtypes among patients without a history of SUD.
OBJECTIVE:Anxiety disorders (AD) and substance use disorders (SUD) commonly co-occur with bipolar disorder. This study was undertaken to assess AD-SUD-bipolar subtype interactions. METHODS: Extensive clinical interview and MINI were used to ascertain DSM-IV diagnoses of rapid cycling bipolar I (RCBPDI) or II (RCBPDII) disorder, SUDs, and ADs including generalized anxiety disorder (GAD), panic disorder (PD), and obsessive-compulsive disorder (OCD). Data at the initial assessment of four studies was used to compare the prevalence differences in ADs between RCBPDI and RCBPDII by using protocol-defined SUD categories, "Never," "Lifetime, but not recent," or "Recent." RESULTS: Five-hundred sixty-six of 568 patients (RCBPDI n=320, RCBPDII n=246) were eligible for analyses. In the "Never" group (n=191), patients with RCBPDI and RCBPDII had similar risk for ADs. In the "Lifetime, but not recent" group (n=195), RCBPDI patients had significantly higher risks for GAD (OR=3.29), PD (OR=2.95), but not OCD, compared with their RCBPDII counterparts. Similarly, in the "Recent" group (n=180), RCBPDI patients also had significantly higher risks for GAD (OR=3.6), PD (OR=3.8), but not OCD, compared with their RCBPDII counterparts. LIMITATIONS: Data were cross-sectional and not all ADs were included. CONCLUSION: In this large cohort of patients with rapid cycling bipolar disorder, risk for having GAD, PD, but not OCD increased significantly in patients with bipolar I disorder compared to their bipolar II counterparts when a history of SUD was present. However, there were no significant differences in the risk for GAD, PD, or OCD between the subtypes among patients without a history of SUD.
Authors: Chantal Henry; Donatienne Van den Bulke; Frank Bellivier; Bruno Etain; Frédéric Rouillon; Marion Leboyer Journal: J Clin Psychiatry Date: 2003-03 Impact factor: 4.384
Authors: Khrista R Boylan; Peter J Bieling; Michael Marriott; Helen Begin; L Trevor Young; Glenda M MacQueen Journal: J Clin Psychiatry Date: 2004-08 Impact factor: 4.384
Authors: Keming Gao; Marcia L Verduin; David E Kemp; Bryan K Tolliver; Stephen J Ganocy; Omar Elhaj; Sarah Bilali; Kathleen T Brady; Robert L Findling; Joseph R Calabrese Journal: J Clin Psychiatry Date: 2008-07 Impact factor: 4.384
Authors: Lewis L Judd; Hagop S Akiskal; Pamela J Schettler; William Coryell; Jack Maser; John A Rice; David A Solomon; Martin B Keller Journal: J Affect Disord Date: 2003-01 Impact factor: 4.839
Authors: Keming Gao; David E Kemp; Zuowei Wang; Stephen J Ganocy; Carla Conroy; Marry Beth Serrano; Martha Sajatovic; Robert L Findling; Joseph R Calabrese Journal: Psychopharmacol Bull Date: 2010
Authors: A Carlo Altamura; Marta Serati; Alessandra Albano; Riccardo A Paoli; Ira D Glick; Bernardo Dell'Osso Journal: Eur Arch Psychiatry Clin Neurosci Date: 2011-02-18 Impact factor: 5.270
Authors: Zuowei Wang; Keming Gao; David E Kemp; Philip K Chan; Mary Beth Serrano; Carla Conroy; Yiru Fang; Stephen J Ganocy; Robert L Findling; Joseph R Calabrese Journal: Psychopharmacol Bull Date: 2010
Authors: Keming Gao; Philip K Chan; Marcia L Verduin; David E Kemp; Bryan K Tolliver; Stephen J Ganocy; Sarah Bilali; Kathleen T Brady; Robert L Findling; Joseph R Calabrese Journal: Am J Addict Date: 2010 Sep-Oct
Authors: Keming Gao; Marzieh Ayati; Mehmet Koyuturk; Joseph R Calabrese; Stephen J Ganocy; Nicholas M Kaye; Hillard M Lazarus; Eric Christian; David Kaplan Journal: Psychopharmacol Bull Date: 2022-02-25
Authors: Keming Gao; Bryan K Tolliver; David E Kemp; Stephen J Ganocy; Sarah Bilali; Kathleen L Brady; Robert L Findling; Joseph R Calabrese Journal: J Clin Psychiatry Date: 2009-07 Impact factor: 4.384
Authors: D E Kemp; L G Sylvia; J R Calabrese; A A Nierenberg; M E Thase; N A Reilly-Harrington; M J Ostacher; A C Leon; T A Ketter; E S Friedman; C L Bowden; D J Rabideau; M Pencina; D V Iosifescu Journal: Acta Psychiatr Scand Date: 2013-03-07 Impact factor: 6.392